A Phase 2 interventional study of Blinatumomab in B-ALL, sponsored by Amgen Research (Munich) GmbH. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 43rd largest by enrollment, is one of 2 that started in 2010, is one of 30 in phase 2, and was the 3rd registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, France, Israel and 3 more countries
Ages 1–30
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 41 · Phase 3 14 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 67 across the 61 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amgen Research (Munich) GmbH, one of the names counted as Amgen. Under that name alone:
Amgen Research (Munich) GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen: 1 open now, 3 under way, 2 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 4th registered.
Amgen’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 2005.
11 of the studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03114865Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | 2026-12-30 |
| NCT05519579Northside Hospital, Inc.Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Amgen’s 20 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.
Relapsed/refractory B-precursor ALL in adult patients is an aggressive malignant disease with dismal prognosis and unmet medical need. Additional therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. The purpose of this study is to investigate the efficacy, safety and tolerability of different doses of the bispecific T-cell engager blinatumomab in adult patients with relapsed/refractory B-precursor ALL. Patrticipants will receive up to five 4-week cycles of intravenous blinatumomab treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
Biological: Blinatumomab
Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
Biological: Blinatumomab
Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
Biological: Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
Also known as: AMG103, MT103, BLINCYTO™
Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Response/Remission (CR): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL Complete Remission with only Partial Hematological Recovery (CRh\*): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL
Time frame: Within the first 2 cycles of treatment, 12 weeks
Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh\*) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria: • Bone marrow blasts ≤ 25%
Time frame: Within the first 2 cycles of treatment, 12 weeks
Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study
A minimal residual disease (MRD) response is defined as MRD \< 10\^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.
Time frame: During the core study treatment period (up to 30 weeks).
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab
The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.
Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days
Time to Hematological Relapse
Time to hematological relapse was measured for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death. Hematological Relapse was defined as: * Proportion of blasts in bone marrow \> 5% * Extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods.
Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.
Relapse-free Survival
Relapse-free survival was measured only for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.
Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.
Overall Survival
Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.
Time frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days.
Number of Participants With Treatment-emergent Adverse Events
Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following: Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death). The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab. A serious adverse event is any untoward medical occurrence or effect, that at any dose: resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.
Time frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.
Steady State Blinatumomab Concentration
The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis. Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.
Time frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.
Clearance of Blinatumomab
Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m\^2/hr) and Css is the steady state concentration.
Time frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles.
Serum Cytokine Peak Levels
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.
Time frame: Samples were collected prior to treatment start (baseline), and at 2, 6, 24, and 48 hours after drug infusion start, and at these same time points when dose is escalated in each treatment cycle.
This study was open to adult patients with relapsed / refractory B-precursor acute lymphoblastic leukemia (ALL).
| Milestone | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg |
|---|---|---|---|
| Started | 7 | 23 | 6 |
| Completed | 2 | 13 | 3 |
| Not completed | 5 | 10 | 3 |
| Withdrew: Adverse event | 4 | 3 | 1 |
| Withdrew: Hematological relapse after remission | 0 | 1 | 1 |
| Withdrew: Remission not achieved in 2 cycles | 1 | 3 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Response/Remission (CR): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL Complete Remission with only Partial Hematological Recovery (CRh\*): * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment | 71.4 (29.0 to 96.3) | 69.6 (47.1 to 86.8) | 66.7 (22.3 to 95.7) | 69.4 (51.9 to 83.7) |
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Full recovery of peripheral blood counts: * Platelets \> 100,000/μL * Hemoglobin ≥ 11 g/dL * Absolute neutrophil count (ANC) \> 1,500/μL
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | ABlinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment | 14.3 (0.4 to 57.9) | 43.5 (23.2 to 65.5) | 66.7 (22.3 to 95.7) | 41.7 (25.5 to 59.2) |
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh\*) was defined by the following criteria: * Less than or equal to 5% blasts in the bone marrow * No evidence of circulating blasts or extramedullar disease * Partial recovery of peripheral blood counts: * Platelets \> 50,000/μL * Hemoglobin ≥ 7 g/dL * ANC \> 500/μL.
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment | 57.1 (18.4 to 90.1) | 26.1 (10.2 to 48.4) | 0.0 (0.0 to 45.9) | 27.8 (14.2 to 45.2) |
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria: • Bone marrow blasts ≤ 25%
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment | 0.0 (0.0 to 41.0) | 8.7 (1.1 to 28.0) | 0.0 (0.0 to 45.9) | 5.6 (0.7 to 18.7) |
A minimal residual disease (MRD) response is defined as MRD \< 10\^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study | 71.4 (29.0 to 96.3) | 73.9 (51.6 to 89.8) | 50.0 (11.8 to 88.2) | 69.4 (51.9 to 83.7) |
The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.
| percentage of participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab |
|---|---|---|---|---|
| Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab | 42.9 | 60.9 | 16.7 | 50.0 |
Time to hematological relapse was measured for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death. Hematological Relapse was defined as: * Proportion of blasts in bone marrow \> 5% * Extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods.
| days | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumimab Overall |
|---|---|---|---|---|
| Time to Hematological Relapse | 240.0 (63.0 to 270.0) | NA (227.0 to NA) | NA (15.0 to NA) | 270.0 (227.0 to NA) |
Relapse-free survival was measured only for participants who achieved a CR or CRh\* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.
| days | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Relapse-free Survival | 137.0 (63.0 to 270.0) | 268.0 (226.0 to 403.0) | NA (15.0 to NA) | 233.0 (175.0 to 291.0) |
Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.
| days | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Overall Survival | 269.0 (165.0 to 482.0) | 300.0 (254.0 to 431.0) | NA (276.0 to NA) | 300.0 (258.0 to 455.0) |
Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following: Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death). The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab. A serious adverse event is any untoward medical occurrence or effect, that at any dose: resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.
| participants | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Any adverse event (AE) | 7 | 23 | 6 | 36 |
| Adverse events of at least CTC grade 3 | 7 | 15 | 5 | 27 |
| Treatment-related adverse events | 7 | 23 | 6 | 36 |
| Related adverse events of at least CTC grade 3 | 7 | 12 | 4 | 23 |
| Serious adverse events | 6 | 13 | 5 | 24 |
| Serious adverse events of at least CTC grade 3 | 6 | 12 | 4 | 22 |
| Serious related adverse events | 4 | 8 | 4 | 16 |
| AEs leading to interruption of blinatumomab | 3 | 6 | 3 | 12 |
| AEs leading to discontinuation of blinatumomab | 4 | 4 | 1 | 9 |
| AEs leading to death | 1 | 4 | 1 | 6 |
The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis. Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.
| pg/mL | Blinatumomab 5 μg | Blinatumomab 15 μg | Blinatumomab 30 μg |
|---|---|---|---|
| Steady State Blinatumomab Concentration | 167 ± 66 | 553 ± 238 | 1180 ± 820 |
Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m\^2/hr) and Css is the steady state concentration.
| L/m^2/hr | Blinatumomab |
|---|---|
| Clearance of Blinatumomab | 1.34 ± 0.61 |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.
| pg/mL | Blinatumomab |
|---|---|
| IL-6: Cycle 1 (N=35) | 2563 ± 5231 |
| IL-6: Cycle 2 (N=22) | 212 ± 477 |
| IL-6: Cycle 3 (N=11) | 21 ± 26 |
| IL-10: Cycle 1 (N=35) | 1302 ± 2563 |
| IL-10: Cycle 2 (N=22) | 351 ± 582 |
| IL-10: Cycle 3 (N=11) | 419 ± 730 |
| IFN-Ɣ: Cycle 1 (N=35) | 467 ± 1824 |
| IFN-Ɣ: Cycle 2 (N=22) | 25 ± 28 |
| IFN-Ɣ: Cycle 3 (N=11) | NA ± NA |
| IL-2: Cycle 1 (N=35) | 36 ± 49 |
| IL-2: Cycle 2 (N=22) | NA ± NA |
| IL-2: Cycle 3 (N=11) | NA ± NA |
| TNF-α: Cycle 1 (N=35) | 60 ± 122 |
| TNF-α: Cycle 2 (N=22) | NA ± NA |
| TNF-α: Cycle 3 (N=11) | NA ± NA |
Collected over From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinatumomab 15 μg | — | 6/7 (85.7%) | 7/7 (100%) |
| Blinatumomab 5/15 μg | — | 13/23 (56.5%) | 23/23 (100%) |
| Blinatumomab 5/15/30 μg | — | 5/6 (83.3%) | 6/6 (100%) |
| Blinatumomab Overall | — | 24/36 (66.7%) | 36/36 (100%) |
| Event | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| Catheter site infectionInfections and infestations | 3/7 | 1/23 | 0/6 | 4/36 |
| NauseaGastrointestinal disorders | 0/7 | 1/23 | 1/6 | 2/36 |
| PyrexiaGeneral disorders | 1/7 | 1/23 | 1/6 | 3/36 |
| Cytokine release syndromeImmune system disorders | 1/7 | 1/23 | 1/6 | 3/36 |
| Candida sepsisInfections and infestations | 0/7 | 0/23 | 1/6 | 1/36 |
| ConvulsionNervous system disorders | 0/7 | 1/23 | 1/6 | 2/36 |
| EncephalopathyNervous system disorders | 1/7 | 1/23 | 1/6 | 3/36 |
| TremorNervous system disorders | 0/7 | 2/23 | 1/6 | 3/36 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/7 | 0/23 | 0/6 | 1/36 |
| LeukopeniaBlood and lymphatic system disorders | 1/7 | 0/23 | 0/6 | 1/36 |
| Event | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Blinatumomab Overall |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 5/7 | 18/23 | 6/6 | 29/36 |
| Oedema peripheralGeneral disorders | 6/7 | 5/23 | 3/6 | 14/36 |
| FatigueGeneral disorders | 5/7 | 8/23 | 5/6 | 18/36 |
| HeadacheNervous system disorders | 2/7 | 11/23 | 4/6 | 17/36 |
| Gamma-glutamyltransferase increasedInvestigations | 4/7 | 3/23 | 0/6 | 7/36 |
| Weight decreasedInvestigations | 4/7 | 2/23 | 2/6 | 8/36 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/7 | 0/23 | 0/6 | 4/36 |
| DiarrhoeaGastrointestinal disorders | 3/7 | 6/23 | 3/6 | 12/36 |
| ChillsGeneral disorders | 2/7 | 2/23 | 3/6 | 7/36 |
| Weight increasedInvestigations | 3/7 | 7/23 | 3/6 | 13/36 |
| Age, Continuous(years) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| Mean | 44.0 ± 21.5 | 38.1 ± 16.7 | 42.5 ± 23.2 | 40.0 ± 18.4 |
| Sex: Female, Male(Participants) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| Female | 3 | 9 | 2 | 14 |
| Male | 4 | 14 | 4 | 22 |
| Race (NIH/OMB)(Participants) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 7 | 22 | 6 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Number of Prior Relapses(participants) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| 0 | 0 | 2 | 1 | 3 |
| 1 | 5 | 15 | 3 | 23 |
| 2 | 2 | 6 | 1 | 9 |
| 3 | 0 | 0 | 1 | 1 |
| Relapsed / refractory Status(participants) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| Primary Refractory | 0 | 2 | 1 | 3 |
| Relapsed | 7 | 21 | 5 | 33 |
| Prior Allogeneic Hematopoietic Stem cell Transplantation (HSCT)(participants) | Blinatumomab 15 μg | Blinatumomab 5/15 μg | Blinatumomab 5/15/30 μg | Total |
|---|---|---|---|---|
| Yes, Sibling | 1 | 1 | 1 | 3 |
| Yes, Unrelated | 2 | 9 | 1 | 12 |
| Yes, Haploidentical (mother/father) | 0 | 0 | 0 | 0 |
| No prior allogeneic HSCT | 4 | 13 | 4 | 21 |
The record gives a start of Oct 2010, a primary completion of Mar 2012 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Amgen Research (Munich) GmbH →